Background: Previously, we detected 19 'new' amino-acid conjugates in the urine of patients with isovaleric acidemia. There is currently a poor understanding of the relationship between the clinical symptoms and the excreted metabolites occurring in these patients, owing to insufficient metabolite characterization and quantification. Consequently, controversial treatment protocols exist, particularly pertaining to dietary protein restriction. Objective: To determine the effect of the previously identified amino-acid conjugates and conventional dietary protein restriction therapy, on the free amino-acid concentrations in isovaleric acidemia patients, to better explain the clinical symptoms and develop more effective therapy. Design: Free amino-acid quantification via liquid chromatography mass spectrometry (LC-MS-MS) was performed on pre-and post-treatment urine or serum samples collected from six isovaleric acidemia patients, previously investigated for the presence of new induced N-isovaleryl and N-acetyl-amino-acid conjugates. Results: Depleted amino-acid concentrations were detected in varying degrees in all six patients and did not recover after conventional treatment. Conclusions: The 19 potentially toxic metabolites previously identified and the consequent amino-acid depletions detected in this study, may explain many of the clinical symptoms associated with isovaleric acidemia. Furthermore, the occurrence of amino-acid depletions in these patients, steers away from the controversial dietary protein restriction treatment protocols, and towards dietary leucine restriction alone with essential amino-acid supplementation, in combination with glycine and L-carnitine supplementation.
Introduction
Isovaleric acidemia is an autosomal-recessive genetic disorder of the enzyme isovaleryl-CoA dehydrogenase, occurring in leucine metabolism (Budd et al., 1967) . The various clinical symptoms associated with this defect include feeding disorders, tachypnea, vomiting, listlessness, lethargy, coma (Tanaka and Rosenberg, 1982) and dehydration (Sweetman and Williams, 1995) . This defect is characterized primarily by the urinary excretion of isovalerylglycine, whereas 3-and 4-hydroxyisovaleric acid, methylsuccinic acid, methylfumaric acid, isovalerylglucuronide, isovalerylglutamic acid, Nisovalerylalanine, N-isovalerylsarcosine, isovalerylcarnitine, 3-hydroxyisoheptanioc acid and alloisoleucine are some intermediates that may further complicate the metabolic profile (Sweetman and Williams, 1995) . Diagnosis of isovaleric acidemia is done on the basis of the clinical symptoms and the presence of isovalerylglycine and 3-hydroxyisovaleric acid (Chalmers and Lawson, 1982) with some of the above-mentioned metabolites also occurring to a greater or lesser extent. Treatment of these patients during acute episodes entails glucose and bicarbonate infusion. Although controversial, a protein restricted diet is often followed to restrict leucine intake (Sweetman and Williams, 1995) . Glycine and L-carnitine supplementation are two newer approaches to treatment during recovery and remission. This is designed to enhance removal of isovaleryl-CoA as nontoxic readily excreted products, isovalerylglycine and isovalerylcarnitine (Sweetman and Williams, 1995) .
Despite the large number of already identified excreted metabolites, their occurrence still does not entirely explain all the clinical symptoms experienced by these patients. The statement made by Duran et al. (1982) : 'The continuing search for ''new'' metabolites may eventually lead to a better understanding of the relationship between the clinical conditions and their biochemical abnormalities' was the motivation for our search for previously unidentified metabolites in isovaleric acidemia (Loots Du et al., 2005) . We subsequently identified, quantified and described, the 19 'new' induced amino-acid metabolites: N-isovaleryl-conjugates of histidine, lysine, tryptophan, a-aminobutyric acid, aspartic acid, serine, phenylalanine, threonine, valine, leucine, asparagine and tyrosine as well as N-acetylated conjugates of threonine, valine, glycine, b-alanine, a-alanine, tyrosine and tryptophan (Loots Du et al., 2005) . In this study, we undertake to determine what effect the previously identified amino-acid conjugates, in combination with conventional protein restriction therapy, has on the free amino-acid concentrations in these individuals. This is done to get a more complete metabolic profile, and a better correlation between the clinical symptoms and the biochemical abnormalities occurring in isovaleric acidemia, which may ultimately lead to better diagnosis and treatments.
Materials and methods

Patients
For the diagnosis of clinically referred cases of organic acidurias in infants, urine sample collection is preferred, as this method is less invasive than blood collection. An isotope amino-acid enrichment study done in neonates, showed a strong correlation of the amino-acid values between plasma and urine (Wykes et al., 1990) . Further research has shown that urinary amino-acid concentrations correlate well to protein intake and with plasma concentrations, and the authors' state 'the effects of protein quality and quantity may be evaluated by measuring urinary amino-acid concentrations alone' (Polberger et al., 1990) . However, owing to the controversy regarding this, when serum samples are occasionally received together with the diagnostic urine samples by the Laboratory of Inborn Metabolic Defects at the NorthWest University, amino-acid analyses are usually done on both samples. In this study, free amino-acid concentrations were examined on pre-and post-urine and/or serum samples of all isovaleric acidemia patients (patients A-F), previously investigated for the presence of new induced N-isovaleryl and N-acetyl-amino-acid conjugates (Loots Du et al., 2005) , and diagnosed between the years 1996 and 2006 by the Laboratory of Inborn Metabolic Defects at the North-West University.
Patient A. A urine sample was collected 10 days after birth with a suspicion of an inborn error of metabolism. The patient showed an abnormal carnitine profile with the excretion of isovalerylcarnitine in addition to high levels of 3-hydroxyisovaleric and isovalerylglycine. This was further complicated by slight ketosis with elevated concentrations of lactic acid (38.63 mmol/mol creatinine) and 3-hydroxybutyric acid (34.7 mmol/mol creatinine). The first follow-up urine sample was received 8 months after commencing treatment.
Patient B. A urine sample was collected 15 days after birth with a clinical profile indicative of an inborn metabolic disorder. The organic acid profile was characteristic of the defect isovaleric acidemia with isovalerylglycine at 578 mmol/mol creatinine, 3-hydroxyisovaleric acid at 360 mmol/mol creatinine, as well as elevated isoavleryl carnitine and lactic acid. The first follow-up urine sample was received 2 months after commencing treatment as the patient was reported to have hypotonia and failure to thrive.
Patient C.
A urine and serum sample was collected 17 days after birth with a suspicion of an inborn error of metabolism. Metabolic disbiosis was evident as very high concentrations of 3-hydroxybutyric acid (971.0 mmol/mol creatinine) and isovalerylglycine (1741.5 mmol/mol creatinine) were detected, in addition to the key diagnostic metabolites, indicating severe ketosis. The first post-treatment follow-up urine and serum samples were received from this patient 5 months after treatment. Urine samples from this patient were used for identifying diagnostic metabolites and aminoacid determinations were done on serum.
Patient D. A urine sample was collected with a suspicion of isovaleric acidemia, at the age of 6 years following diagnosis of the patient's younger sibling with the same defect. The sample showed elevated levels of isovalerylglycine. Almost no 3-hydroxyisovaleric acid was detected. Despite this the patient was confirmed as having isovaleric acidemia. A follow-up urine sample was received 1 month after commencing treatment.
Patient E. A urine and serum sample was collected at 4 years of age with a suspicion of an inborn error of metabolism, following diagnosis of this patient's younger sibling. The first follow-up urine and serum sample was received 5 months after commencing treatment. Urine samples were used for diagnosis and both urine and serum for free amino-acid concentrations.
Patient F. A urine and serum sample was collected 9 days after birth with a suspicion of an inborn error of metabolism.
In addition to the diagnostic metabolites characteristic of isovaleric acidemia, slight ketosis also occurred. The first follow-up urine sample was received 1 month after commencing treatment. Unfortunately, no follow-up serum sample was received for this patient.
After diagnosis with isovaleric acidemia, all six patients received protein-restricted diets, calculated as half the recommended dietary protein intake for healthy individuals of similar ages. Hence, preterm infants received 1.5 g of protein/kg/day, which was recalculated as the patient's protein requirements changed with age. Similarly, the dosages of L-carnitine and glycine supplementation were dependent on the amount of diagnostic metabolites detected in the urine of these patients.
Electrospray ionization mass spectrometry (ESI-MS-MS) aminoacid analysis
Amino acids were analysed by isotope dilution ESI-MS-MS. For the application of this technique, two basic 'mixtures' were prepared: an amino-acid calibration standard (Budd et al., 1967) and the serum or urine samples (Tanaka and Rosenberg, 1982) . The amino-acid calibration standard as a quantification reference was made up by using 100 ml of the amino-acid calibration standard (Pickering Laboratories, Space Park Way, Mountain View, CA, USA), and 400 ml of an amino-acid isotope internal standard stock solution made up to a concentration such that the concentrations of the standard amino acids in the final analysis mixture are 2594.7, 1175.2, 394.2, 1198.5 and 1275.1 mmol/l for the amino acids glycine-D 2 , ring-D 5 -phenylalanine, methyl-D 3 -methionine, D 8 -valine and D 10 -isoleucine, respectively (synthesized by Dr Herman J ten Brink of the Academic Hospital VU, Netherlands). The urine or serum samples were prepared by adding 400 ml of the amino-acid isotope standard stock solution to 10 ml of the sample. These were then dried at 701C under a vacuum. Butanolic HCl (3 N) was added and butylated for 10 min at a temperature of 701C and then dried at 701C under a vacuum. Dried samples were resuspended in 100 ml of acetonitrile/water (50:50) with 1% formic acid followed by centrifugation for 10 min to remove any materials that may block the capillary tube. The samples were introduced into the electrospray source at a rate of 10 ml/min.
Results
By quantifying the free amino-acid concentrations in the urine or serum of six isovaleric acidemia patients, before and after conventional treatment (protein restriction, glycine and L-carnitine supplementation), we determined the effect of the abnormal amino-acid conjugation and protein restriction on the depletion of the free amino acids in these individuals. All amino acids were seen to be depleted to varying degrees in the various patients when compared to the standardized amino-acid values determined for healthy individuals (Table 1) . This is most likely owing to their involvement in conjugation reactions with acetyl-and isovaleryl-CoA, as described previously (Loots Du et al., 2005) , in addition to a protein restricted diet.
As seen in Table 2 , however better in some individuals, treatment did not fully restore the free amino-acid Table 1 Amino-acid concentrations in the urine and serum of untreated isovaleric acidemia patients Amino-acid depletion in isovaleric acidemia DT Loots et al concentrations (except for the previously depleted glycine). This depletion is seen to persist in the subsequent posttreatment follow-up samples collected, even in the earliest diagnosed patients who have supplied follow-up samples for up to 6 years (results not shown). Methionine was also seen to be depleted in these individuals despite the absence of a methionine conjugate in the previous study (Loots Du et al., 2005) . It is, however, not unlikely that conjugates of methionine are formed and undergo further chemical or metabolic changes. Furthermore, the similarities of serum and urinary amino-acid depletions analysed for patients E and F confirm observations by Wykes et al. (1990) and Polberger et al. (1990) .
Discussion
The synthesis of acetylated amino acids in the urine of patients with inborn errors of metabolism is a frequent occurrence (Bremer et al., 1981) . Most of these are formed for the purpose of detoxification. During the past three decades a number of acyl-amino-acid conjugates with amino-acid moieties other than glycine or glutamine, that is alanine, glutamic acid and serine, have been detected in a number of mammalian species including man. In patients suffering from propionic acidemia, propionyl-conjugates of alanine, serine and glutamic acid were recently detected in our laboratory (Van der Westhuizen et al., 2000) . Furthermore, isovaleric acidemia patients sometimes become ketotic with a consequential acetyl-CoA increase. On the basis of this, we identified 19 new N-isovaleryl-and N-acetyl-amino-acid conjugates in the urine of patients with isovaleric acidemia (Loots Du et al., 2005) . Glycine-N-acylase is seen to use a variety of amino acids as substrates (Van der Westhuizen et al., 2000) . Furthermore, isovaleryl-CoA serves as an exceptional secondary substrate for these conjugation reactions (Lehnert, 1981) . Thus, glycine-N-acylase seems the most likely candidate for these reactions. Lehnert (1983) detected the presence of isovaleryl glutamic acid in isovaleric acidemia and suggested N-acetylglutamate synthetase to be responsible for this. On the basis of this and the structural similarities of glutamate and aspartate, one would expect the same enzyme to be involved in the formation of isovalerylaspartate. Sonoda and Tatibana (1983) , however, isolated this enzyme and determined propionyl-CoA to be the only other acyl-CoA to substitute acetyl-CoA as an acyl donor. They further report aspartate not to act as an alternate acyl acceptor in these enzyme reactions.
N-isovalerylhistidine, -lysine, -tryptophan and -acetyltryptophan occurred in large quantities in the urine of patients with isovaleric academia (Loots Du et al., 2005) . Isovaleryl conjugates of the amino acids leucine, phenylalanine, threonine and valine occurred to a lesser extent. The amino acids involved in these conjugation reactions are essential amino acids with additional functions above and beyond protein synthesis. Conjugation of these amino acids may contribute significantly to the clinical symptoms of isovaleric acidemia, not only because of the conjugation products themselves being potentially toxic, but also because of a depletion of these amino acids owing to excretion of the conjugation products, in combination to dietary protein Table 2 Amino-acid concentrations in the urine and serum of treated isovaleric acidemia patients restriction. Deficiencies in the above-mentioned free amino acids are seen to be associated with the following clinical symptoms: retarded growth, eating disorders, decreased immunity, neurological disorders, thrombocytopenia, neutropenia, pancytopenia, cyanosis, listlessness and lethargy (Cohn et al., 1977; Huether, 1986; Contamira et al., 1991; van der Schot et al., 1994; Mero, 1999; Balch and Balch, 2000; Bassit et al., 2002) . These clinical symptoms are identical to those associated with isovaleric acidemia. For this reason, we feel that depletion of the amino acids involved in the detoxification reactions occurring in isovaleric acidemia patients, may be in part responsible for the majority of the clinical symptoms associated with this disease. Additionally, these results give a more complete biochemical profile and a better correlation to the clinical symptoms associated with this disease, which up to now has been unclear. This not only gives us a better understanding of the disease, but also gives clues to more effective treatment. Protein restriction therapy in the diet of isovaleric acidemia has long been a topic of debate. Millington et al. (1987) obtained results indicating that the turnover of endogenous protein, rather than diet, is the main cause for toxic metabolites in isovaleric academia, and suggest that dietary protein restriction is futile and that effective therapy should be directed at the suppression of endogenous catabolism. Current therapy for isovaleric acidemia in this study involved glycine and L-carnitine treatment in addition to the traditional dietary protein restrictions. Although glycine and L-carnitine treatment showed significant lowering of 3-hydroxyisovaleric acid, it however had very little effect on restoring the depleted amino acids, even after treatment periods of up to 6 years. On the basis of these results, we suggest a similar treatment protocol as followed by Saudubray et al. (1976) leucine (only) dietary restrictions (instead of total protein restrictions) with essential amino-acid supplementation, in addition to standard treatment protocols of glycine and L-carnitine supplementation. However, studies would still need to be performed to determine if the depletion of amino acids in isovaleric acidemia pretreatment urine and plasma samples could be corrected by the use of specific formulas.
